FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test
An FDA advisory committee voted in favor of approving GRAIL's Galleri multi-cancer early detection test.
GRAIL, Inc.
Early cancer detection company whose Galleri multi-cancer early detection blood test uses methylation-based liquid biopsy to screen for a signal shared by more than 50 cancers before symptoms appear.
Company Info
Clinical Development Pipeline
Galleri
Target: cfDNA methylation signaturesRecent News
Leadership Team
Joshua Ofman
Chief Executive Officer
Eric Fung
Chief Medical Officer
Paul Ciccolella
Chief Financial Officer